Endoscopic remission was achieved in 4/10 people on SKYRIZI—meaning little to no visible evidence of active Crohn’s—at 1 year.†‡
SKYRIZI RESULTS
The FIRST AND ONLY IL-23i for Crohn’s That Can Deliver Both CLINICAL REMISSION and ENDOSCOPIC IMPROVEMENT
IL-23 inhibitor (IL-23i) with clinical remission and endoscopic response co-primary measures in label at both 12 and 52 weeks.
RESULTS You Can FEEL
Significant symptom relief as early as 4 weeks, including:
- less abdominal pain
- fewer bowel movements
The majority of people on SKYRIZI achieved long-lasting
remission at 1 year.*
*Clinical remission was measured at 52 weeks.
And Your Doctor Can SEE
Monitoring endoscopic changes is an important part of managing your Crohn’s and reaching your treatment goals. That’s because, even if you’re feeling better, damaging inflammation may continue to occur in the intestinal lining. Your doctor can see this on an endoscopy.
Endoscopic remission was achieved in 4/10 people on SKYRIZI—meaning little to no visible evidence of active Crohn’s at 1 year.†‡
†Based on areas that were assessed on endoscopy.
‡In the clinical trial, this measure was not tested for a difference between SKYRIZI and placebo.
Dosing Information: Adults with Crohn’s disease will receive their starter doses with SKYRIZI through a vein in the arm (intravenous infusion) in a healthcare facility by a healthcare provider. After completing the starter doses, patients will receive SKYRIZI as an injection under the skin (subcutaneous injection) using the prefilled cartridge with On-Body Injector (OBI). SKYRIZI is available as 180 mg or 360 mg maintenance dosage options. Your doctor will decide what maintenance dose is right for you.
patients who Achieved Clinical remission on skyrizi
meaning few or no symptoms
CD-1 Study at Week 12
600 mg
IV infusion
45%
25% placebo
CD-2 Study at Week 12
600 mg
IV infusion
42%
20% placebo
CD-3 Study at Week 52
180 mg/1.2 mL
maintenance injection
61%
46% placebo
CD-3 Study at Week 52
360 mg/2.4 mL
maintenance injection
57%
46% placebo
patients who Achieved Endoscopic Improvement On Skyrizi
meaning at least a 50% visible improvement of the intestinal lining
CD-1 Study at Week 12
600 mg
IV infusion
40%
12% placebo
CD-2 Study at Week 12
600 mg
IV infusion
29%
11% placebo
CD-3 Study at Week 52
180 mg/1.2 mL
maintenance injection
50%
22% placebo
CD-3 Study at Week 52
360 mg/2.4 mL
maintenance injection
48%
22% placebo
Individual results may vary. Ask your doctor about SKYRIZI.
CD-1 (n=336) and CD-3 (n=252) clinical studies were a mixed population of patients with or without prior biologic failure. CD-2 (n=191) clinical study consisted of patients who failed at least one biologic.
CD-3 evaluated SKYRIZI 180 mg (n=135) and SKYRIZI 360 mg (n=117) maintenance doses in patients who had achieved clinical response (a reduction in CDAI of at least 100 points from baseline) after completion of 12-week SKYRIZI induction treatment (CD-1 and CD-2).
Up Next
Recommended for You
Learn how SKYRIZI can be administered at home after 3 starter doses and proper training by a healthcare professional.